Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is an incurable lung disease with a poor prognosis. Fibroblasts and myofibroblasts are the key cells in the fibrotic process. Recently two drugs, pirfenidone and nintedanib, were approved for clinical use as they are able to slow down the disease progr...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Respir Res
Auteurs principaux: Lehtonen, Siri T., Veijola, Anniina, Karvonen, Henna, Lappi-Blanco, Elisa, Sormunen, Raija, Korpela, Saara, Zagai, Ulrika, Sköld, Magnus C., Kaarteenaho, Riitta
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2016
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4743320/
https://ncbi.nlm.nih.gov/pubmed/26846335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-016-0328-5
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires